National Academies Press: OpenBook

Malaria Control During Mass Population Movements and Natural Disasters (2003)

Chapter: Appendix A: Description of Antimalarial Drugs

« Previous: References
Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×

APPENDIX A
Description of Antimalarial Drugs

QUININE

Quinine was first isolated from Chinchona bark in 1820 and has since been the fundamental chemotherapeutic tool for the treatment of malaria, especially severe disease. Quinine and its dextroisomer, quinidine, are rapidly acting schizontocides that target the erythrocytic asexual stages of all malaria parasites. It is available in both oral and parenteral preparations and can be used in infants and pregnant women. Side effects include nausea, dysphoria, blurred vision, and tinnitus and typically resolve after treatment has ended. P. falciparum from most areas of the world responds well to quinine; thus, shortened courses of quinine can be used in conjunction with a second drug to reduce the likelihood of quinine-associated side effects. P. falciparum from many areas of Southeast Asia requires full-course quinine treatment in conjunction with a second drug (see Table 3-3), such as tetracycline.

CHLOROQUINE

Chloroquine is a 4-aminoquinoline derivative of quinine first synthesized in 1934. Historically, it has been the drug of choice for the treatment of nonsevere or uncomplicated malaria and for chemoprophylaxis. Chloroquine acts primarily against erythrocytic asexual stages, although it has gametocidal properties. Because of widespread resistance to this drug,

Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×

its usefulness is increasingly limited. Where chloroquine retains efficacy it can be safely used for treatment or prophylaxis of infants and pregnant women. Side effects are uncommon and not generally serious. These include nausea, headache, gastrointestinal disturbance, and blurred vision. Some patients, especially if dark skinned, experience pruritus.

AMODIAQUINE

Amodiaquine is a drug closely related to chloroquine that fell out of favor because of a high incidence of adverse reactions (including agranulocytosis and hepatitis), primarily when used for prophylaxis, and drug resistance patterns similar to chloroquine. This drug is currently being reevaluated, especially as a possible component in artesunate-containing combination-therapy regimens. Concern over toxicity remains, however.

ANTIFOL COMBINATION DRUGS

These drugs are various combinations of dihydrofolate reductase inhibitors (proguanil, chlorproguanil, pyrimethamine, and trimethoprim) and sulfa drugs (dapsone, sulfalene, sulfamethoxazole, sulfadoxine, and others). Although these drugs have antimalarial activity when used alone, parasitological resistance can develop rapidly. When used in combination, they produce a synergistic effect on the parasite and can be effective even in the presence of resistance to the individual components. Typical combinations include sulfadoxine/pyrimethamine (Fansidar), sulfalene/pyrimethamine (Metakelfin), and sulfamethoxazole/trimethoprim (cotrimoxazole). Proguanil is often used in combination with chloroquine for prophylaxis in areas of moderate chloroquine resistance, although studies suggest that minimal additional benefit is derived, especially with prolonged exposure (Lobel et al., 1993; Steffen et al., 1993). Side effects are uncommon; however, severe allergic reactions can occur. When used prophylactically among American travelers, sulfadoxine/pyrimethamine has been associated with a high incidence of severe cutaneous reactions (1 per 5,000 to 8,000 users) and mortality (1 per 11,000 to 25,000 users; Miller et al., 1986). These side effects do not appear to occur as frequently when the drug is used for treatment. Concerns about sulfa drug use during pregnancy are outweighed by the known risks to mother and fetus of untreated malaria. Finally, use of folate supplementation concurrently with antifol antimalarials may increase the frequency of treatment failure (van Hensbroek et al., 1995).

Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×

Another promising antifol combination, chlorproguanil and dapsone, is currently being tested in Africa and elsewhere. Also known as “LapDap,” this particular combination is innately more effective than sulfadoxine/ pyrimethamine (even in areas where resistance is present) and also has a much shorter elimination half-life, which may decrease the chances for development of resistance (Watkins et al., 1997; Mutabingwa et al., 2001). Conversely, the shorter half-life requires that it be given over 3 days rather than in a single dose.

TETRACYCLINES

Tetracycline and derivatives such as doxycycline are very potent antimalarials and are used for either treatment or prophylaxis. In areas where response to quinine has deteriorated, tetracyclines are often used in combination with quinine to improve cure rates. Tetracyclines are also used in conjunction with shortened courses of quinine to decrease the likelihood of quinine-associated side effects (provided parasites are susceptible to quinine). Tetracyclines should not be used during pregnancy, breast-feeding, or in children under age 8. Common side effects include nausea, vomiting, diarrhea, Candida superinfections, and photosensitivity.

PRIMAQUINE

Primaquine, an 8-aminoquinoline, is primarily used as a tissue schizonticide for the purpose of reducing the likelihood of relapse due to hypnozoites of P. vivax and P. ovale. Studies have shown that primaquine has reasonably good efficacy (74 percent against P. falciparum and 90 percent against P. vivax) when used for prophylaxis (Baird et al., 1995). Although it has activity against blood-stage asexual parasites, the concentrations required to achieve blood schizonticidal action are toxic; primaquine is also a potent gametocidal drug. People with glucose-6-phosphate dehydrogenase (G6PD) deficiencies can experience severe and potentially fatal hemolytic anemia if treated with primaquine. The most severe Mediterranean B variant and related Asian variants of G6PD deficiency can occur at high rates among some groups and in some regions; Kurdish Jews (62 percent), Saudi Arabia (13 percent), Myanmar (20 percent), and southern China (6 percent). Migration, mutation, and intermarriage have spread these variants throughout the world. Primaquine should not be used in pregnancy.

Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×

Tafenoquine, a synthetic primaquine analog, is currently being tested. It is highly effective against both liver and blood stages of malaria. Because of its long half-life (14 days versus 6 hours for primaquine), tafenoquine may prove to be a valuable chemoprophylactic drug (Lell et al., 2000). As for primaquine, tafenoquine can result in hemolysis among patients with G6PD deficiency.

MEFLOQUINE

Mefloquine is a quinoline-methanol derivative of quinine. Mefloquine can be used either therapeutically or prophylactically in most areas with multidrug-resistant malaria. Resistance to mefloquine, however, occurs frequently in parts of Southeast Asia; sporadic resistance has been reported in areas of Africa and South America. Mefloquine has been associated with a relatively high incidence of neuropsychiatric side effects when used at treatment doses but is otherwise well tolerated. Although not licensed for use during pregnancy and in very young infants, mefloquine appears to be safe and effective in both groups.

HALOFANTRINE

Halofantrine is a phenanthrene-methanol compound with activity against the erythrocytic stages of the malaria parasite. Its use has been especially recommended in areas with multidrug-resistant falciparum. Studies have indicated, however, that the drug can produce cardiac conduction abnormalities (specifically, prolongation of the PR and QT interval1), limiting its usefulness (Nosten et al., 1993). A subsequent study suggests that cardiac abnormalities are dose dependent and can be severe in patients with preexisting cardiopathy; the authors suggest that electrocardiography be conducted on all patients prior to treatment with halofantrine (Monlun et al., 1995). A micronized formulation has improved halofantrine’s poor oral bioavailability; however, it should be given on an empty stomach. Fatty foods dramatically increase absorption, increasing the risk of cardiac complications. Recrudescences can occur with one round of treatment, and, especially when treating nonimmune individuals, a second course should

1  

PR and QT intervals are specific points on an electrocardiogram. They are the intervals between the P and R wave forms and between the Q and T wave forms, respectively.

Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×

be given 7 days later. Retreatment of patients who had failed mefloquine therapy with halofantrine was less successful than primary treatment with halofantrine, suggesting the possibility of clinical cross-resistance between the two drugs (Wongsrichanalai et al., 1992; ter Kuile et al., 1993). Halofantrine therapy after mefloquine or quinine therapy also increases the risk of cardiac problems.

CLINDAMYCIN

Clindamycin has some antimalarial activity but is a poor choice compared to the other available antimalarial drugs. It is a slow-acting schizonticide and should only be used in combination with a fast-acting schizonticide, such as quinine, especially when treating patients with little or no immunity to malaria (Pukrittayakamee et al., 2000b; Parola et al., 2001). Although clindamycin may be useful for treatment of pregnant women and very young children (Pukrittayakamee et al., 2000a) more effective drugs are available that can be used in these groups (such as mefloquine or even, perhaps, mefloquine + artesunate).

ARTEMISININ COMPOUNDS

A number of sesquiterpine lactone compounds have been synthesized from the plant Artemisia annua (artesunate, artemether, artether). Benefits of use for severe malaria include rapid parasite clearance times and faster fever resolution than occurs with quinine. Preliminary results of studies to determine if this faster action produces improved survival suggest that there is quicker improvement of coma following treatment with artemisinins (Taylor et al., 1993; Salako et al., 1994). When used alone, especially for durations of less than 5 to 7 days, recrudescence rates are high. For nonsevere malaria, artemisinins are most successfully used in combination with a second drug (Nosten et al., 1994a). The best-documented combination therapy is that using mefloquine and 3 days of artesunate.

A fixed-dose preparation of lumefantrine and artemether is commercially available (Co-artem or Riamet). Lumefantrine (previously known as benflumetol) is an aryl-amino alcohol antimalarial compound. Although related chemically, in practice, lumefantrine does not appear to have cardiac effects similar to halofantrine (van Vugt et al., 1999). This combination is marketed in two packaging schemes: a six-dose (24-tablet) package for use by nonimmune patients, and a four-dose (16-tablet) package for use by

Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×

semiimmune patients. Until studies have conclusively shown adequate efficacy of the four-dose regimen among semiimmune populations, all patients should probably be treated with a full six-dose regimen (van Vugt et al., 2000). No data exist to prove the safety of lumefantrine use during pregnancy; thus, lumefantrine should not be used to treat pregnant women.

ATOVAQUONE PLUS PROGUANIL (MALARONE)

This drug is a fixed-dose antimalarial combination of 250 mg of atovaquone and 100 mg of proguanil. Atovaquone is a hydroxynaptho-quinone that is currently being used mostly to treat opportunistic infections in immunosuppressed patients. Because of a high incidence of recrudescence when used alone, atovaquone is given in combination with proguanil (Looareesuwan et al., 1996a; Radloff et al., 1996). Treatment is with 1,000 mg of atovaquone and 400 mg of proguanil daily for 3 days. Malarone is reportedly effective against erythrocytic forms of P. vivax (Looareesuwan et al., 1996a). Although there is some concern about resistance developing rapidly to this combination, Malarone currently appears to be highly effective against most drug-resistant malaria parasites.

PYRONARIDINE

Pyronaridine is a drug synthesized and used in China for over 20 years. While it was reportedly 100 percent effective in one trial in Cameroon, the drug was only 63 to 88 percent effective in Thailand (Ringwald et al., 1996; Looareesuwan et al., 1996b). Further testing is required before pyronaridine can be recommended for use.

Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×
Page 145
Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×
Page 146
Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×
Page 147
Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×
Page 148
Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×
Page 149
Suggested Citation:"Appendix A: Description of Antimalarial Drugs." National Research Council. 2003. Malaria Control During Mass Population Movements and Natural Disasters. Washington, DC: The National Academies Press. doi: 10.17226/10539.
×
Page 150
Next: Appendix B: Methodology for Efficacy Assessment of In Vivo Malaria Therapy »
Malaria Control During Mass Population Movements and Natural Disasters Get This Book
×
Buy Paperback | $50.00 Buy Ebook | $39.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Admittedly, the world and the nature of forced migration have changed a great deal over the last two decades. The relevance of data accumulated during that time period can now be called into question. The roundtable and the Program on Forced Migration at the Mailman School of Public Health of Columbia University have commissioned a series of epidemiological reviews on priority public health problems for forced migrants that will update the state of knowledge. Malaria Control During Mass Population Movements and Natural Disasters -- the first in the series, provides a basic overview of the state of knowledge of epidemiology of malaria and public health interventions and practices for controlling the disease in situations involving forced migration and conflict.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!